Cutting edge: interactions through the IL-10 receptor regulate autoimmune diabetes

Area of Science:

• Immunology
• Endocrinology
• Transgenic Mouse Models

Background:

• BDC2.5/nonobese diabetic (NOD) transgenic mice express a diabetogenic T cell receptor (TCR) but do not spontaneously develop high-incidence diabetes.
• Evidence suggests T cell regulation, specifically involving CTLA-4 and endogenous TCR alpha-chain rearrangements, governs diabetes onset in this model.
• Understanding the mechanisms of immune regulation is crucial for deciphering autoimmune diabetes pathogenesis.

Purpose of the Study:

• To investigate the mechanisms of immune regulation in BDC2.5/NOD transgenic mice.
• To determine the role of T cell regulation in preventing spontaneous diabetes development.
• To elucidate the specific involvement of cytokines, such as IL-10, in regulating diabetes onset.

Main Methods:

• Transfer of activated spleen cells from young and old BDC2.5/NOD mice to NOD-scid recipients to assess diabetogenicity.
• Treatment with anti-IL-10 receptor (anti-IL-10R) antibodies to block IL-10 signaling.
• Administration of anti-IL-10R to young BDC2.5/NOD mice to evaluate the impact on diabetes development.

Main Results:

• Activated spleen cells from young BDC2.5/NOD mice transferred diabetes to NOD-scid recipients, while cells from older mice did not.
• The failure of splenocytes from older mice to transfer diabetes was attributed to dominant immune regulation.
• Treatment with anti-IL-10R induced diabetes in 6-week-old BDC2.5/NOD mice, indicating a critical role for endogenous IL-10.

Conclusions:

• T cell-mediated immune regulation is a critical factor controlling diabetes onset in BDC2.5/NOD mice.
• Endogenous IL-10 is a key regulatory cytokine that suppresses diabetes development in this model.
• Targeting IL-10 pathways may offer therapeutic strategies for autoimmune diabetes.